Cabaletta Bio (NASDAQ:CABA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cabaletta Bio (NASDAQ:CABA) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Other analysts have also issued reports about the stock. Wells Fargo & Company lowered their price objective on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a report on Thursday, October 15th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research report on Monday, August 24th. William Blair upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Cabaletta Bio in a report on Tuesday, September 1st. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cabaletta Bio has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Cabaletta Bio Stock Performance

Shares of Cabaletta Bio stock opened at $1.50 on Friday. The business has a 50 day moving average of $2.09 and a 200 day moving average of $2.82. Cabaletta Bio has a 52 week low of $1.18 and a 52 week high of $4.23.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, equities research analysts forecast that Cabaletta Bio will post -1.29 EPS for the current fiscal year.

Institutional Trading of Cabaletta Bio

Several hedge funds have recently bought and sold shares of CABA. Legal & General Group Plc purchased a new position in Cabaletta Bio during the 2nd quarter valued at approximately $34,000. HighTower Advisors LLC bought a new stake in shares of Cabaletta Bio in the 2nd quarter worth about $34,000. Kestra Advisory Services LLC bought a new stake in shares of Cabaletta Bio in the 1st quarter worth about $32,000. SummitTX Capital L.P. bought a new stake in shares of Cabaletta Bio in the 1st quarter worth about $34,000. Finally, StoneX Group Inc. purchased a new stake in shares of Cabaletta Bio during the 3rd quarter valued at about $26,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.